You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 39 No. 6, June 1982 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Drug Trial of Superoxide Dismutase in Duchenne's Muscular Dystrophy

Lawrence Z. Stern, MD; Steven P. Ringel, MD; Fred A. Ziter, MD; Kerstin B. Menander-Huber, MD, PhD; Victor Ionasescu, MD; Richard J. Pellegrino, MD; Russell D. Snyder, MD

Arch Neurol. 1982;39(6):342-346.


Abstract

• A multicenter, randomized, doubleblind, placebo-controlled drug trial in Duchenne's muscular dystrophy, evaluating a superoxide dismutase in 51 ambulatory patients for 18 months was conducted. Fourteen aspects of muscle strength and five of functional ability, as well as serum creatine phosphokinase (CPK) level were studied. The total change in strength, function, and CPK level did not differ significantly in the two groups. The testing method used was reliable in assessing the natural history of Duchenne's dystrophy and would, therefore, be useful in future multicenter drug trials.



Author Affiliations

From the Departments of Neurology, the Universities of Arizona, Tucson (Dr Stern); Colorado, Denver (Dr Ringel); Utah, Salt Lake City (Dr Ziter); Iowa, Iowa City (Dr Ionasescu); Nebraska, Omaha (Dr Pellegrino); and New Mexico, Albuquerque (Dr Snyder); and Diagnostic Data Inc, Mountain View, Calif (Dr Menander-Huber).


Footnotes

Accepted for publication Oct 1, 1981.

Read in part before the International Symposium on Muscular Dystrophy Research, Venice, Italy, April 11, 1980.

Reprint requests to Department of Internal Medicine (Neurology), University of Arizona Health Sciences Center, Tucson, AZ 85724 (Dr Stern).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The role of reactive oxygen species in the hearts of dystrophin-deficient mdx mice
Williams and Allen
Am. J. Physiol. Heart Circ. Physiol. 2007;293:H1969-H1977.
ABSTRACT | FULL TEXT  

The role of free radicals in the pathophysiology of muscular dystrophy
Tidball and Wehling-Henricks
J. Appl. Physiol. 2007;102:1677-1686.
ABSTRACT | FULL TEXT  

Oxygen-Derived Free Radicals
Hinder and Stein
Arch Surg 1991;126:104-105.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1982 American Medical Association. All Rights Reserved.